Holen Sie sich die Stockscreener-App
0.5108
27.19%
0.1092
Handel nachbörslich:
.48
-0.0308
-6.03%
Schlusskurs vom Vortag:
$0.4016
Offen:
$0.4
24-Stunden-Volumen:
4.14M
Relative Volume:
18.89
Marktkapitalisierung:
$19.29M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-10.21M
KGV:
-0.8744
EPS:
-0.5842
Netto-Cashflow:
-
1W Leistung:
+21.50%
1M Leistung:
-1.75%
6M Leistung:
-42.54%
1J Leistung:
-53.56%
1-Tages-Spanne:
$0.36
$0.5257
1-Wochen-Bereich:
$0.36
$0.5257
52-Wochen-Spanne:
$0.25
$1.98
Neurosense Therapeutics Ltd Stock (NRSN) Company Profile
Firmenname
Neurosense Therapeutics Ltd
Sektor
Branche
Telefon
-
Adresse
-
Compare NRSN vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NRSN
Neurosense Therapeutics Ltd
|
0.5108 | 13.23M | 0 | -10.21M | 0 | -0.5842 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Neurosense Therapeutics Ltd Aktie (NRSN) Neueste Nachrichten
Neurosense Therapeutics Stock Price Forecast. Should You Buy NRSN? - StockInvest.us
NeuroSense CEO Details Phase 3 ALS Trial Plans, Canada Filing and Nasdaq Compliance Efforts - The Globe and Mail
Amyotrophic Lateral Sclerosis Pipeline Shows Strong Momentum as 80+ Pharma Companies in the Race | DelveInsight - openPR.com
NeuroSense Issues CEO Letter to Shareholders - Nasdaq
NeuroSense Therapeutics publishes CEO shareholder letter on Phase 3 PrimeC plans - Bitget
NeuroSense Therapeutics (NRSN) Slips to $0.47 as Bulls Defend Key Support FloorNHNL Ratio - dars.gov.et
Global Neurodegenerative Disease Market is Expected to - GlobeNewswire
NRSN Q2 2025 Earnings: Narrower Loss Beats Estimates as Pre-Revenue Pipeline AdvancesEarnings Revision Downgrade - vinanet.vn
NeuroSense Advances PrimeC Toward December 2026 Health Canada Filing After Completing Pre-NDS Process - TipRanks
NeuroSense Completes PrimeC Pre-NDS Process and Advances Toward December 2026 Filing with Health Canada - GuruFocus
Health Canada review path for PrimeC: NeuroSense (NASDAQ: NRSN) - Stock Titan
NeuroSense Therapeutics (NRSN) Jumps 11.35% to $0.52, Nears Key Resistance at $0.55Revenue Growth Stocks - dars.gov.et
NeuroSense Therapeutics Ltd. SEC Filing (Aug 3, 2026) - Stock Titan
NeuroSense Therapeutics Calls August 26 Shareholder Vote on Wide-Range Reverse Share Split - TipRanks
NeuroSense Therapeutics (NRSN) seeks reverse split amid Nasdaq compliance push - Stock Titan
NeuroSense Therapeutics (NRSN) sets $150M shelf and $3.8M ATM share plan - Stock Titan
NeuroSense Therapeutics (NRSN) Plunges 14% – Testing Critical Support at $0.46Sentiment Shift - vinanet.vn
Neurosense Therapeutics is a buy, this analyst says - Cantech Letter
Neurosense Therapeutics Ltd expected to post breakeven results a shareEarnings Preview - TradingView
Neurosense Therapeutics Ltd. Revenue Breakdown – FWB:H1Z - TradingView
Neurosense Therapeutics Ltd - TradingKey
Neurosense Therapeutics Ltd (NRSN) Cash Flow - TradingKey
NRSN|Neurosense Therapeutics Ltd|Price:0.602|Chg%:-0.048 - TradingKey
Neurosense Therapeutics Ltd (NRSN) Valuation: PE, PB & Fair Value Analysis - TradingKey
NRSN|Neurosense Therapeutics Ltd|Price:0.500|Chg%:-0.003 - TradingKey
TradingKey - TradingKey
NeuroSense Therapeutics (NRSN) Gains 3.08% as Stock Tests Key Resistance at $0.70Upthrust Pattern - vinanet.vn
NeuroSense Moves PrimeC Toward Health Canada Drug Submission for ALS - TipRanks
NeuroSense Therapeutics (NASDAQ: NRSN) eyes Canada NDS for ALS drug - Stock Titan
NeuroSense Advances PrimeC Toward New Drug Submission to Health Canada for ALS - PR Newswire
NRSN Q2 2025 Earnings: Narrower-than-Expected Loss Fails to Soothe ShareholdersHealthcare Earnings Report - vinanet.vn
NeuroSense Therapeutics (NRSN) Faces Headwinds: Stock Retreats 5.6% to $0.69 Amid Sector PressureMarket Profile - vinanet.vn
NeuroSense Therapeutics (NRSN) Slips 2.6% as Stock Tests Key Support at $0.65Cumulative Volume - vinanet.vn
NeuroSense Therapeutics (NRSN) Slides 2.3% as Sellers Test Key Support at $0.66Calendar Spread Trade - dars.gov.et
NeuroSense Therapeutics (NRSN) Edges Higher as Key Support HoldsEquity Put Call - dars.gov.et
NeuroSense Therapeutics Ltd. (NRSN) Latest Stock News & Headlines - Yahoo Finance
NeuroSense to Participate in Roth-Hosted KOL Webinar on the Future of ALS Treatment: "A Quest to Outrun ALS" - Nasdaq
Enterprise value to revenue forward of NeuroSense Therapeutics Ltd. – NASDAQ:NRSN - TradingView
Price to earnings forward of NeuroSense Therapeutics Ltd. – NASDAQ:NRSN - TradingView
NeuroSense Therapeutics Ltd. Warrant 2021-open end Financial Disclosures & SEC Filings - TradingView
NeuroSense bolsters case for multi-target Alzheimer’s strategy - Longevity.Technology
NRSN Q2 2025 Earnings: Narrower-Than-Expected Loss Highlights Cost DisciplineBasic EPS Analysis - dars.gov.et
NeuroDex ExoSORT Platform Demonstrates Treatment-Responsive Blood-Based Measurement of Neuronal TDP-43 in People Living with ALS - Bakersfield.com
NeuroSense (NRSN) Achieves Key Milestone in ALS Study - GuruFocus
NeuroSense Hits Key TDP-43 Endpoint in Phase 2b ALS Trial, Advances Toward Phase 3 - TipRanks
NeuroSense Says Phase 2b Trial of PrimeC in Amyotrophic Lateral Sclerosis Meets Primary Endpoint - marketscreener.com
NeuroSense (NRSN) Phase 2b ALS study cuts TDP-43, eyes Phase 3 - Stock Titan
NeuroSense Achieves Primary Endpoint in Phase 2b ALS Study with Statistically Significant Reduction of TDP-43, the Defining Pathological Hallmark of ALS - Nasdaq
NeuroSense reports positive Phase 2b ALS data - grafa.com
NeuroSense reports Phase 2 biomarker findings for PrimeC in Alzheimer’s disease - BioSpectrum Asia
Neurosense Therapeutics Ltd. Actuals & Estimates (NASDAQ:NRSN) - TradingView
Finanzdaten der Neurosense Therapeutics Ltd-Aktie (NRSN)
Umsatz
Nettogewinn
Free Cashflow
ENV
Neurosense Therapeutics Ltd-Aktie (NRSN) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Ben-Noon Alon | Chief Executive Officer |
Jun 16 '26 |
Buy |
0.80 |
250,000 |
200,000 |
4,534,233 |
0.86%
0.31%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):